When should hepatitis B antiviral therapy be discontinued?

When to Stop Hepatitis B Antiviral Therapy

HBsAg loss (with or without anti-HBs seroconversion) is the only universally safe stopping point for hepatitis B antiviral therapy across all patient populations. 1, 2

Universal Stopping Criterion

• After confirmed HBsAg loss—defined as two negative HBsAg tests at least 6 months apart—continue therapy for an additional 6–12 months of consolidation before final discontinuation. 1, 2
• HBsAg loss represents a functional cure with significantly lower risk of hepatocellular carcinoma development and rare virological relapse in non-cirrhotic patients. 2
• Even after HBsAg loss, patients with cirrhosis should continue indefinite therapy due to persistent HCC risk and potential for severe hepatitis flares. 1, 2

HBeAg-Positive Patients

Primary Recommendation

• Continue antiviral therapy indefinitely until HBsAg loss is achieved. This is the safest approach. 1

Conditional Alternative (High Relapse Risk)

• Therapy may be stopped after HBeAg seroconversion to anti-HBe positivity together with undetectable HBV DNA, followed by at least 12 months of consolidation therapy. 3, 1, 2
• This approach carries substantial risk: approximately 38% develop ALT flares after cessation, the majority experience recurrent viremia, and prospective data show that all HBeAg-positive patients who stopped without HBsAg loss experienced virological relapse with 75% requiring retreatment. 1, 4
• A consolidation period of at least 18 months and early virological response (HBV DNA <20 IU/mL at 6 months during therapy) improve sustained remission rates. 5
• Before considering this approach, patients must undergo liver biopsy or transient elastography to confirm only mild fibrosis (F0–F1). Those with fibrosis stage F2 or greater should remain on indefinite therapy. 1

HBeAg-Negative Patients

Standard Recommendation

• The American Association for the Study of Liver Diseases explicitly recommends lifelong treatment for HBeAg-negative patients; the sole accepted stopping point is HBsAg loss. 1, 2
• This conservative stance reflects high relapse rates (70–75%) and risk of immune-escape mutants. 1

Conditional Alternative (Not Routinely Advised)

• The European Association for the Study of the Liver permits discontinuation in highly selected non-cirrhotic patients after ≥3 years of sustained virological suppression (undetectable HBV DNA on three separate tests ≥6 months apart). 3, 1, 2
• This strategy demands extremely close post-treatment monitoring and should be limited to patients who can guarantee rigorous follow-up. 1
• Longer on-therapy remission improves outcomes: approximately 50% maintain virological remission three years after stopping if they had >2 years of undetectable HBV DNA during treatment. 3, 1
• Recent data show that duration of nucleoside analogue treatment <60 months and ALT levels ≥2× upper limit of normal at treatment initiation independently predict virological relapse. 6
• Prospective studies demonstrate that HBeAg-negative patients without cirrhosis can be safely withdrawn with long-term remission and high rates of HBsAg loss (4 of 7 patients in one study), whereas patients who were initially HBeAg-positive should not be withdrawn because clinical relapse was frequent and often severe. 4

Patients with Cirrhosis

Compensated Cirrhosis

• Lifelong antiviral therapy is mandatory; discontinuation is permissible only after confirmed HBsAg loss. 1, 2
• Even after HBsAg loss, these patients require lifelong hepatocellular carcinoma surveillance. 1

Decompensated Cirrhosis

• Indefinite therapy is absolutely required; stopping is contraindicated unless HBsAg loss plus sustained anti-HBs seroconversion is maintained for 6–12 months. 3, 1, 2
• Overt hepatitis flares and life-threatening episodes have been reported in cirrhotic patients who discontinue therapy. 3

Absolute Contraindications to Stopping

• Never discontinue therapy in patients with any degree of cirrhosis (compensated or decompensated) unless HBsAg loss is achieved. 1, 2
• Never stop therapy in patients >60 years old unless HBsAg loss occurs. 1, 2
• Never discontinue in HBeAg-negative patients who have not achieved HBsAg loss. 1
• Never stop in patients who were HBeAg-positive at therapy initiation without HBsAg loss, due to high risk of severe relapse. 1

Mandatory Post-Discontinuation Monitoring Protocol

• Monitor ALT and HBV DNA monthly for the first 3 months after stopping, then every 3 months during the first year. 3, 1, 2
• Check HBeAg/anti-HBe every 3–6 months in the first year. 2
• Continue HBV DNA and liver function tests every 3–6 months beyond the first year. 2
• Check HBsAg/anti-HBs every 6–12 months to monitor for HBsAg loss or reversion. 2
• Maintain HCC surveillance every 6 months indefinitely, even after HBsAg loss. 2
• Close monitoring is critical as relapse can lead to acute hepatitis flare, decompensation, or fulminant hepatitis. 2

Retreatment Criteria

• Restart antiviral therapy if HBV DNA rises to ≥2,000 IU/mL together with elevated ALT, or if there is any evidence of hepatic decompensation. 1
• The cumulative probability of retreatment is 18% at 3 months and 26% at 12 months, being significantly affected by pretreatment fibrosis severity. 7

Critical Pitfalls to Avoid

• Do not stop therapy based solely on undetectable HBV DNA without meeting other criteria, as most patients will relapse. 2
• Do not use HBeAg seroconversion alone as an endpoint without adequate consolidation therapy, as this is an imperfect endpoint with high relapse rates. 2
• Do not assume that HBeAg seroconversion guarantees a durable response; the majority of patients experience recurrent viremia after stopping. 1
• Do not assume HBsAg loss is permanent, as HBsAg reversion can occur, requiring continued monitoring. 2
• Do not discontinue therapy abruptly without establishing a close monitoring plan, as hepatitis flares can be severe and life-threatening. 1

Special Populations

• For patients on immunosuppressive therapy, continue antiviral prophylaxis for at least 12 months after cessation of immunosuppressive therapy (24 months for rituximab), regardless of HBsAg status. 2
• In patients unable to afford long-term treatment, if discontinuation is unavoidable after ≥5 years of treatment with undetectable HBV DNA for the past 3 years, most patients maintain low HBV DNA and normal ALT levels despite virological relapse, but this approach requires intensive monitoring and willingness to promptly restart treatment. 2